Summary

Machine-generated summary

North Macedonia is procuring medicines for biological therapy for 2026. The purchase covers 41 items of anticancer and related medicines, including targeted therapies and monoclonal antibodies such as alectinib, atezolizumab, axitinib, bevacizumab (originator and biosimilar), cobimetinib, cetuximab, erlotinib, fulvestrant, oxaliplatin in two strengths, pembrolizumab, pazopanib, palbociclib in three strengths, pemetrexed, ribociclib, sunitinib, sorafenib, trastuzumab emtansine, pertuzumab/trastuzumab combinations, abiraterone, vemurafenib, osimertinib, lorlatinib, nivolumab, denosumab, ipilimumab, durvalumab, dabrafenib, trametinib, darolutamide, avelumab, olaparib, inavolisib and capivasertib, with stated strengths and pack sizes.

Description

Procurement of medicines for 2026 Biological therapy 1 L01ED03 Alectinib 150 mg; 2 L01FF05 Atezolizumab 1875 mg/15 ml; 3 L01EK01 Axitinib; 4 L01FG01 Bevacizumab originator; 5 L01FG01 Bevacizumab biosimilar; 6 L01EE02 Cobimetinib; 7 Cetuximab solution for infusion 5 mg/mlx20 ml; 8 L01XE03 Erlotinib; 9 L02BA03 Fulvestrant 250 mg; 10 L01XA03 Oxaliplatin 50 mg; 11 L01XA03 Oxaliplatin 100 mg; 12 L01FF02 Pembrolizumab; 13 L01EX03 Pazopanib; 14 L01XE33 Palbociclib 125 mg; 15 L01XE33 Palbociclib 100 mg; 16 L01XE33 Palbociclib 75 mg; 17 L01BA04 Pemetrexed 25mg/ml; 18 L01EF02 Ribociclib 200 mg; 19 L01EX01 Sunitinib 50mg; 20 L01XE05/L01EX02 Sorafenib 200 mg; 21 L01FD03 Trastuzumab emtansine 100 mg/15 ml; 22 L01XC014 Trastuzumab emtansine 160 mg/20 ml; 23 L01XY02 Pertuzumab/ trastuzumab 1200 mg/600 mg; 24 L01XY02 Pertuzumab/ trastuzumab 600 mg/600 mg; 25 L02BX03 Abiraterone 250 mg; 26 L02BX03 Abiraterone 500 mg; 27 L01XE15 Vemurafenib 240 mg; 28 L01XE35 Osimertinib 80 mg; 29 L01ED05 Lorlatinib 100 mg; 30 L01FF01 Nivolumab 40 mg; 31 L01FF01 Nivolumab 100 mg; 32 M05BX04 Denosumab 120 MG; 33 L01XC11 Ipilimumab 5mg/mlx10ml; 34 L01FF03 Durvalumab 50 mg/mlx10ml; 35 L01XE23 Dabrafenib 75 mg; 36 L01EE01 Trametinib 2 mg; 37 L02BB06 Darolutamide 300 mg; 38 L01FF04 Avelumab 20 mg/mlx10ml; 39 L01XK01 Olaparib 150mg (56 tab); 40 L01EM06 Inavolisib 9 mg; 41 L01EX27 Capivasertib 200mg

Show the full description

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Report an error in this notice

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 12 hours ago

View the official notice

Certificate equivalence across the EU (eCertis)

The buyer

Full buyer profile

University clinic of radiotherapy and oncology

North Macedonia

notices in the register: 13

This buyer has no award history in this sector yet. Usual winners, Medical equipment & pharmaceuticals - North Macedonia

Company	Wins	Total awarded	Last win
АЛКАЛОИД КОНС ДООЕЛ; БИО МЕДИКА ДООЕЛ Скопје; ВЕНОФИТ ДООЕЛ Скопје; AD Д-Р ПАНОВСКИ; ПРОМЕДИКА ДОО Скопје; ФАРМА ТРЕЈД ДООЕЛ	1	€470,776	Aug 2025
Production, trade and services company BI-MEK DOO Skopje	1	€385,540	Jul 2026
BI-MEK DOO Skopje	1		Sep 2026
UNI-MEDIKAL PST DOOEL import-export	1		Apr 2026

Based on 4 awards with a linked company profile over the last 2 years.

13 open tenders right now

North Macedonia - Medical consumables - Procurement of medical supplies No deadline published
North Macedonia - Repair and maintenance services of medical and precision equipment - Full service (regular maintenance and interventional servicing) for therapy machines No deadline published
North Macedonia - Pharmaceutical products - Laboratory reagents and materials No deadline published

Market context

TED - Tenders Electronic Daily (Publications Office of the EU) publishes no value for this notice, so it cannot be placed among the open notices of its sector. The official documents may state one.

open now in Medical equipment & pharmaceuticals: 10,748
median open notice: €144,729

Similar tenders